Synapse - Mark Kris

Results (223)

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

Journal Article

Riely, G. J.; Pao, W.; Pham, D.; Li, A. R.; Rizvi, N.; Venkatraman, E. S.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Miller, V. A.
Clinical Cancer Research (2006)

Fulltext@MSK | Save

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Journal Article

Balak, M. N.; Gong, Y.; Riely, G. J.; Somwar, R.; Li, A. R.; Zakowski, M. F.; Chiang, A.; Yang, G.; Ouerfelli, O.; Kris, M. G.; more...
Clinical Cancer Research (2006)

Fulltext@MSK | Save

EGFR and KRAS mutational analysis of mucinous pneumonic bronchiololavelolar carcinomas

Meeting Abstract

Zakowski, M.; Ladanyi, M.; Kris, M.; Rusch, V.; Pao, W.
Lung Cancer (2005)

Fulltext@MSK | Save

A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC

Meeting Abstract

Rizvi, N.; Pao, W.; Miller, V.; Rusch, V.; Heelan, R.; Ladanyi, M.; Ginex, P.; Tyson, L.; Zakowski, M.; Kris, M.
Lung Cancer (2005)

Fulltext@MSK | Save

Clinical characteristics and natural history of patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations treated with erlotinib or gefitinib

Meeting Abstract

Riely, G. J.; Miller, V. A.; Pao, W.; Zakowski, M.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

EGFR mutation, immumohistochemistry (IHC) and chromogenic in situ hybridization (CISH) as predictors of sensitivity to erlotinib and gefitinib in patients (pts) with NSCLC

Meeting Abstract

Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Hussain, S.; Ladanyi, M.; Heelan, R. T.; Kris, M. G.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Clinical testing for EGFR mutations in non-small cell lung cancer: Single laboratory experience with 253 consecutive cases

Meeting Abstract

Li, A. R.; Riely, G. J.; Zakowski, M. F.; Pao, W.; Pan, Q.; Ma, Y.; Miller, V. A.; Kris, M. G.; Ladanyi, M.
Journal of Molecular Diagnostics (2005)

Fulltext@MSK | Save

Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung

Meeting Abstract

Hussain, S.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.; Pao, W.; Riely, G.; Rizvi, N.; Gomez, J. E.; Miller, V.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

A phase I dose escalation trial of pulsatile high dose gefitinib and docetaxel in patients with an advanced solid tumor

Meeting Abstract

Fury, M. G.; Kris, M.; Solit, D.; Pfister, D. G.; Azzoli, C. G.; Henry, R.; Su, Y. B.; Rizvi, N.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel

Journal Article

Solit, D. B.; She, Y.; Lobo, J.; Kris, M. G.; Scher, H. I.; Rosen, N.; Sirotnak, F. M.
Clinical Cancer Research (2005)

Fulltext@MSK | Save